Wilson Sonsini - ECP

insight detail

Wilson Sonsini Advises Terray Therapeutics on $60 Million Series A

  • 02/16/22
  • Client Highlights
  • Life Sciences
  • Biotech

On February 15, 2022, Terray Therapeutics, an AI-powered drug discovery company, announced the closing of a $60 million Series A financing to advance its novel tNova platform and its discovery partnerships. The financing was led by Madrona Venture Group with participation from a broad syndicate of new and existing investors, including Two Sigma Ventures, Digitalis Ventures, KdT Ventures, Goldcrest Capital, XTX Ventures, Sahsen Ventures, Greentrail Capital, and Alexandria Venture Investments. This financing follows a previously unannounced $20 million seed round co-led by Digitalis Ventures and Two Sigma Ventures.

Wilson Sonsini Goodrich & Rosati represented Terray Therapeutics in both financing transactions. The team includes Michael Coke, Myra Sutanto Shen, Amanda Urquiza, Tyler Lefky, Matty Gallas, Jasbir Bains, and Henry Yen.

For more information, please see Terray Therapeutics' press release.

ECP Attorneys:

Copyright © 2022 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.